A
Alain C. Jung
Researcher at University of Strasbourg
Publications - 23
Citations - 729
Alain C. Jung is an academic researcher from University of Strasbourg. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cetuximab. The author has an hindex of 12, co-authored 23 publications receiving 604 citations.
Papers
More filters
Journal ArticleDOI
Biological and Clinical Relevance of Transcriptionally Active Human Papillomavirus (HPV) Infection in Oropharynx Squamous Cell Carcinoma
Alain C. Jung,Jenny Briolat,Régine Millon,Aurélien de Reyniès,David S. Rickman,Emilie Thomas,Joseph Abecassis,Christine Clavel,Bohdan Wasylyk +8 more
TL;DR: Important criteria required to predict clinically active HPV infection are highlighted, new biological pathways implicated in HPV tumorigenesis are identified and the understanding of HPV‐HNSCC physiopathology is increased to develop new targets for therapy.
Journal ArticleDOI
CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis.
Alain C. Jung,Sébastien Guihard,Sylvie Krugell,Sonia Ledrappier,Alexandra Brochot,Véronique Dalstein,Sylvie Job,Aurélien de Reyniès,Georges Noël,Bohdan Wasylyk,Christine Clavel,Joseph Abecassis +11 more
TL;DR: The results suggest that an increased cytotoxic T‐cell‐based antitumor immune response is involved in improved prognosis of patients with HPV‐positive tumors.
Journal ArticleDOI
A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome and miRNome analysis
Alain C. Jung,Sylvie Job,Sonia Ledrappier,Christine Macabre,Joseph Abecassis,Aurélien de Reyniès,Bohdan Wasylyk +6 more
TL;DR: In this article, a genome-wide integrated analysis of four omic sets of data was conducted to identify prognostic squamous cell carcinoma molecular subgroups and potential biomarkers, which led to better selection of patients at higher risk, identification of relevant molecular pathways of metastasis, and potential to discover biomarkers and drug targets.
Journal ArticleDOI
DDB2: A Novel Regulator of NF-κB and Breast Tumor Invasion
Marie Ennen,Rémi Klotz,Nadège Touche,Sophie Pinel,Claire Barbieux,Vanessa Besancenot,Emilie Brunner,Denise Thiebaut,Alain C. Jung,Sonia Ledrappier,Lionel Domenjoud,Joseph Abecassis,François Plénat,Stéphanie Grandemange,Philippe Becuwe +14 more
TL;DR: Understanding of how breast cancer cells progress to an invasive phenotype is enlightened and potential clinical interest in DDB2 as a prognostic marker or therapeutic target in this setting is underscored.